SK125798A3 - Method of killing target cells in harvested cell populations with one or more immunotoxins - Google Patents
Method of killing target cells in harvested cell populations with one or more immunotoxins Download PDFInfo
- Publication number
- SK125798A3 SK125798A3 SK1257-98A SK125798A SK125798A3 SK 125798 A3 SK125798 A3 SK 125798A3 SK 125798 A SK125798 A SK 125798A SK 125798 A3 SK125798 A3 SK 125798A3
- Authority
- SK
- Slovakia
- Prior art keywords
- cells
- immunotoxins
- cell
- antibodies
- bone marrow
- Prior art date
Links
- 239000002596 immunotoxin Substances 0.000 title claims abstract description 105
- 230000002637 immunotoxin Effects 0.000 title claims abstract description 105
- 229940051026 immunotoxin Drugs 0.000 title claims abstract description 105
- 231100000608 immunotoxin Toxicity 0.000 title claims abstract description 105
- 238000000034 method Methods 0.000 title claims abstract description 74
- 230000002147 killing effect Effects 0.000 title claims abstract description 16
- 210000004027 cell Anatomy 0.000 claims abstract description 212
- 210000000130 stem cell Anatomy 0.000 claims abstract description 40
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 20
- 239000011886 peripheral blood Substances 0.000 claims abstract description 20
- 230000003211 malignant effect Effects 0.000 claims abstract description 13
- 238000001727 in vivo Methods 0.000 claims abstract description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 47
- 208000026310 Breast neoplasm Diseases 0.000 claims description 47
- 206010028980 Neoplasm Diseases 0.000 claims description 35
- 108091007433 antigens Proteins 0.000 claims description 32
- 102000036639 antigens Human genes 0.000 claims description 32
- 239000000427 antigen Substances 0.000 claims description 31
- 230000000694 effects Effects 0.000 claims description 31
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 claims description 20
- 239000008280 blood Substances 0.000 claims description 15
- 210000004369 blood Anatomy 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 239000003053 toxin Substances 0.000 claims description 12
- 231100000765 toxin Toxicity 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 10
- 230000002625 immunotoxic effect Effects 0.000 claims description 9
- 231100000110 immunotoxic Toxicity 0.000 claims description 8
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims description 6
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims description 6
- 102100034263 Mucin-2 Human genes 0.000 claims description 6
- 101001133081 Homo sapiens Mucin-2 Proteins 0.000 claims description 5
- 102100034256 Mucin-1 Human genes 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 4
- 101000972284 Homo sapiens Mucin-3A Proteins 0.000 claims description 4
- 210000000683 abdominal cavity Anatomy 0.000 claims description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 101710082714 Exotoxin A Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 239000002619 cytotoxin Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 101100504181 Arabidopsis thaliana GCS1 gene Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000000115 thoracic cavity Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 abstract description 41
- 238000000338 in vitro Methods 0.000 abstract description 2
- 210000004881 tumor cell Anatomy 0.000 description 46
- 238000002474 experimental method Methods 0.000 description 36
- 238000000746 purification Methods 0.000 description 28
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 21
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 21
- 201000011510 cancer Diseases 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 18
- 238000011081 inoculation Methods 0.000 description 13
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 238000002512 chemotherapy Methods 0.000 description 10
- 231100000419 toxicity Toxicity 0.000 description 10
- 230000001988 toxicity Effects 0.000 description 10
- 108700012359 toxins Proteins 0.000 description 10
- 230000006378 damage Effects 0.000 description 9
- 230000003394 haemopoietic effect Effects 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 239000012894 fetal calf serum Substances 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 108090001008 Avidin Proteins 0.000 description 5
- 231100000699 Bacterial toxin Toxicity 0.000 description 5
- 239000000688 bacterial toxin Substances 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 210000000601 blood cell Anatomy 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 229960004679 doxorubicin Drugs 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000010899 nucleation Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000003021 clonogenic effect Effects 0.000 description 4
- 210000005087 mononuclear cell Anatomy 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 208000035404 Autolysis Diseases 0.000 description 3
- 206010057248 Cell death Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000002960 bfu-e Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 210000004976 peripheral blood cell Anatomy 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000028043 self proteolysis Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102100022497 Mucin-3A Human genes 0.000 description 2
- 108010063954 Mucins Proteins 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000006727 cell loss Effects 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000002095 exotoxin Substances 0.000 description 2
- 231100000776 exotoxin Toxicity 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- FPKVOQKZMBDBKP-UHFFFAOYSA-N 1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 FPKVOQKZMBDBKP-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241001416181 Axis axis Species 0.000 description 1
- 108090001069 Chymopapain Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 1
- 101000623904 Homo sapiens Mucin-17 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101150114927 MUC1 gene Proteins 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 108010008705 Mucin-2 Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010084592 Saporins Proteins 0.000 description 1
- 206010041549 Spinal cord compression Diseases 0.000 description 1
- ISWQCIVKKSOKNN-UHFFFAOYSA-L Tiron Chemical compound [Na+].[Na+].OC1=CC(S([O-])(=O)=O)=CC(S([O-])(=O)=O)=C1O ISWQCIVKKSOKNN-UHFFFAOYSA-L 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229960002976 chymopapain Drugs 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 231100001224 moderate toxicity Toxicity 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 229940029345 neupogen Drugs 0.000 description 1
- 210000002261 nucleate cell Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 210000002568 pbsc Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 229940051173 recombinant immunotoxin Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
- C12N5/0093—Purging against cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO961031A NO961031D0 (no) | 1996-03-13 | 1996-03-13 | Fremgangsmåte til å drepe uönskede målceller |
| PCT/NO1997/000074 WO1997033611A1 (en) | 1996-03-13 | 1997-03-12 | Method of killing target cells in harvested cell populations with one or more immunotoxins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK125798A3 true SK125798A3 (en) | 1999-05-07 |
Family
ID=19899150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1257-98A SK125798A3 (en) | 1996-03-13 | 1997-03-12 | Method of killing target cells in harvested cell populations with one or more immunotoxins |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7198787B2 (ja) |
| EP (1) | EP0954329B1 (ja) |
| JP (1) | JP2000507230A (ja) |
| CN (1) | CN1218411A (ja) |
| AT (1) | ATE222122T1 (ja) |
| AU (1) | AU710184B2 (ja) |
| BR (1) | BR9708049A (ja) |
| CA (1) | CA2248620A1 (ja) |
| DE (1) | DE69714775T2 (ja) |
| HU (1) | HUP9901597A3 (ja) |
| IL (1) | IL126014A0 (ja) |
| NO (1) | NO961031D0 (ja) |
| NZ (1) | NZ331763A (ja) |
| PL (1) | PL328804A1 (ja) |
| RU (1) | RU2182493C2 (ja) |
| SK (1) | SK125798A3 (ja) |
| TR (1) | TR199801795T2 (ja) |
| WO (1) | WO1997033611A1 (ja) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8921102B2 (en) | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
| US7496291B2 (en) * | 2006-03-21 | 2009-02-24 | Hewlett-Packard Development Company, L.P. | Method and apparatus for interleaved image captures |
| US8137912B2 (en) | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
| WO2007147074A2 (en) | 2006-06-14 | 2007-12-21 | Living Microsystems, Inc. | Use of highly parallel snp genotyping for fetal diagnosis |
| US8372584B2 (en) | 2006-06-14 | 2013-02-12 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
| US20080050739A1 (en) | 2006-06-14 | 2008-02-28 | Roland Stoughton | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
| CA3069081C (en) | 2008-09-20 | 2023-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
| AU2009305550B2 (en) * | 2008-10-17 | 2014-06-12 | Dana-Farber Cancer Institute, Inc. | MUC-1 cytoplasmic domain peptides as inhibitors of cancer |
| CN102665748A (zh) | 2009-05-27 | 2012-09-12 | 达娜-法勃肿瘤研究所公司 | 使用muc1拮抗剂抑制炎症 |
| CN102127148B (zh) * | 2010-01-14 | 2013-04-03 | 中国农业科学院北京畜牧兽医研究所 | 血管内皮细胞表面决定簇部分多肽及其应用 |
| ES2641877T3 (es) * | 2011-05-06 | 2017-11-14 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Inmunotoxina recombinante dirigida a mesotelina |
| CN107748256B (zh) * | 2017-10-11 | 2020-04-14 | 厦门骁科码生物科技有限公司 | 一种循环肿瘤细胞的液体活检检测方法 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4219411A (en) | 1978-09-18 | 1980-08-26 | California Institute Of Technology | Cell sorting apparatus |
| US4230685A (en) | 1979-02-28 | 1980-10-28 | Northwestern University | Method of magnetic separation of cells and the like, and microspheres for use therein |
| US4510244A (en) | 1980-04-17 | 1985-04-09 | The Board Of Trustees Of The Leland Stanford Jr. University | Cell labeling with antigen-coupled microspheres |
| AU563827B2 (en) | 1982-07-01 | 1987-07-23 | Millipore Corp. | Filtration apparatus |
| US4659678A (en) | 1982-09-29 | 1987-04-21 | Serono Diagnostics Limited | Immunoassay of antigens |
| US4704255A (en) | 1983-07-15 | 1987-11-03 | Pandex Laboratories, Inc. | Assay cartridge |
| US4920061A (en) | 1984-03-02 | 1990-04-24 | The University Of Texas System | Biological magnetic colloids |
| US4752569A (en) | 1984-06-21 | 1988-06-21 | The Regents Of The University Of California | Sialylated Lewisx epitope, antibodies and diagnosis |
| US5019497A (en) | 1984-11-09 | 1991-05-28 | Lennart Olsson | Human squamous lung carcinoma cell specific antigens and antibodies |
| US4710472A (en) | 1985-09-25 | 1987-12-01 | The United States Of America As Represented By The Secretary Of The Navy | Magnetic separation device |
| US5076950A (en) | 1985-12-20 | 1991-12-31 | Syntex (U.S.A.) Inc. | Magnetic composition for particle separation |
| EP0241042A3 (en) | 1986-04-11 | 1988-05-04 | Hitachi, Ltd. | A method for cell analysis |
| US4895706A (en) | 1986-10-28 | 1990-01-23 | Costar Corporation | Multi-well filter strip and composite assemblies |
| US4857452A (en) | 1986-12-04 | 1989-08-15 | E. I. Du Pont De Nemours And Company | Assay for carcinoma of breast, colon and ovary |
| US5194300A (en) | 1987-07-15 | 1993-03-16 | Cheung Sau W | Methods of making fluorescent microspheres |
| US5322678A (en) | 1988-02-17 | 1994-06-21 | Neorx Corporation | Alteration of pharmacokinetics of proteins by charge modification |
| US5256532A (en) | 1988-05-02 | 1993-10-26 | Zynaxis Technologies, Inc. | Methods, reagents and test kits for determination of subpopulations of biological entities |
| FR2638848B1 (fr) | 1988-11-04 | 1993-01-22 | Chemunex Sa | Procede de detection et/ou de dosage dans un milieu liquide ou semi-liquide d'au moins une substance organique, biologique ou medicamenteuse soluble, par une methode d'agglutination |
| DE68919715T2 (de) | 1988-12-28 | 1995-04-06 | Stefan Miltenyi | Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien. |
| US5185254A (en) * | 1988-12-29 | 1993-02-09 | The Wistar Institute | Gene family of tumor-associated antigens |
| GB8905001D0 (en) | 1989-03-04 | 1989-04-19 | Univ Leicester | Screening for natural products of microbial metabolism |
| WO1990010692A1 (en) | 1989-03-15 | 1990-09-20 | University Of Florida | Monoclonal antibody for use in detection and treatment of childhood leukemia |
| US5081030A (en) | 1989-04-25 | 1992-01-14 | The Johns Hopkins University | Release of cells from affinity matrices |
| DE3919923A1 (de) | 1989-06-19 | 1990-12-20 | Behringwerke Ag | Magnetische protein-konjugate, verfahren zu ihrer herstellung und ihre verwendung |
| DE3919873A1 (de) | 1989-06-19 | 1990-12-20 | Behringwerke Ag | Magnetische protein-konjugate, verfahren zu ihrer herstellung und ihre verwendung |
| GB8916859D0 (en) | 1989-07-24 | 1989-09-06 | Dynal As | Hapten linking |
| JPH05503632A (ja) * | 1989-12-14 | 1993-06-17 | スローン ― ケターリング・インスティチュート・フォー・キャンサー・リサーチ | モノクローナル抗体ｍ１９５の超可変領域の治療的使用およびその構築 |
| GB8929297D0 (en) | 1989-12-29 | 1990-02-28 | Dynal As | Method of separation |
| GB9007966D0 (en) | 1990-04-09 | 1990-06-06 | Dynal As | Antigen/anti-antigen cleavage |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| US5340719A (en) | 1990-11-23 | 1994-08-23 | Corporation Coulter | Method and apparatus for optically screening microscopic cells |
| JPH05107249A (ja) | 1991-02-04 | 1993-04-27 | Toyobo Co Ltd | リガンド・レセプター反応の高感度検出法 |
| US5491068A (en) | 1991-02-14 | 1996-02-13 | Vicam, L.P. | Assay method for detecting the presence of bacteria |
| AU2115092A (en) | 1991-10-08 | 1993-04-22 | Eastman Kodak Company | Method, test device and kit for assay of specific binding ligand using controlled flow through filtration membrane |
| US5290707A (en) | 1991-11-25 | 1994-03-01 | The United States Of America As Represented By The Secretary Of The Army | Method for detection of microorganisms |
| US5256542A (en) | 1992-03-09 | 1993-10-26 | Tanox Biosystems, Inc. | Selecting low frequency antigen-specific single B lymphocytes with correction for background noise |
| CA2131090A1 (en) | 1992-03-20 | 1993-09-21 | Peter Leonard Grant | Method and apparatus for the analysis of biological material |
| US5422277A (en) | 1992-03-27 | 1995-06-06 | Ortho Diagnostic Systems Inc. | Cell fixative composition and method of staining cells without destroying the cell surface |
| WO1994002016A1 (en) * | 1992-07-28 | 1994-02-03 | Steven Kessler | Methods for positive immunoselection of stem cells |
| WO1994007138A1 (en) | 1992-09-14 | 1994-03-31 | Fodstad Oystein | Detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations |
| ES2123063T3 (es) | 1992-09-14 | 1999-01-01 | Stanford Res Inst Int | Marcadores convertidores al alza para ensayos biologicos y otros mediante tecnicas de excitacion laser. |
| FR2700010B1 (fr) | 1992-12-24 | 1995-03-17 | Rocher Yves Biolog Vegetale | Méthode et dispositif pour tester la réactivité de cellules à l'égard de produits. |
| US5374531A (en) | 1993-03-22 | 1994-12-20 | Zynaxis, Inc. | Immunoassay for determination of cells |
| US5514340A (en) | 1994-01-24 | 1996-05-07 | Magnetix Biotechnology, Inc. | Device for separating magnetically labelled cells |
| NO180658C (no) | 1994-03-10 | 1997-05-21 | Oeystein Fodstad | Fremgangsmåte og anordning for deteksjon av spesifikke målceller i spesialiserte eller blandede cellepopulasjoner og opplösninger som inneholder blandede cellepopulasjoner |
| US6017719A (en) * | 1994-06-14 | 2000-01-25 | Nexell Therapeutics, Inc. | Positive and positive/negative cell selection mediated by peptide release |
| AUPN214095A0 (en) | 1995-04-03 | 1995-04-27 | Australian Water Technologies Pty Ltd | Method for detecting microorganisms using flow cytometry |
-
1996
- 1996-03-13 NO NO961031A patent/NO961031D0/no unknown
-
1997
- 1997-03-12 TR TR1998/01795T patent/TR199801795T2/xx unknown
- 1997-03-12 PL PL97328804A patent/PL328804A1/xx unknown
- 1997-03-12 IL IL12601497A patent/IL126014A0/xx unknown
- 1997-03-12 AT AT97916665T patent/ATE222122T1/de not_active IP Right Cessation
- 1997-03-12 CA CA002248620A patent/CA2248620A1/en not_active Abandoned
- 1997-03-12 HU HU9901597A patent/HUP9901597A3/hu unknown
- 1997-03-12 SK SK1257-98A patent/SK125798A3/sk unknown
- 1997-03-12 DE DE69714775T patent/DE69714775T2/de not_active Expired - Fee Related
- 1997-03-12 AU AU25229/97A patent/AU710184B2/en not_active Ceased
- 1997-03-12 NZ NZ331763A patent/NZ331763A/xx unknown
- 1997-03-12 CN CN97194599A patent/CN1218411A/zh active Pending
- 1997-03-12 RU RU98118574/14A patent/RU2182493C2/ru not_active IP Right Cessation
- 1997-03-12 WO PCT/NO1997/000074 patent/WO1997033611A1/en not_active Application Discontinuation
- 1997-03-12 EP EP97916665A patent/EP0954329B1/en not_active Expired - Lifetime
- 1997-03-12 JP JP9532482A patent/JP2000507230A/ja active Pending
- 1997-03-12 BR BR9708049A patent/BR9708049A/pt unknown
- 1997-03-12 US US09/125,751 patent/US7198787B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO1997033611A1 (en) | 1997-09-18 |
| NO961031D0 (no) | 1996-03-13 |
| AU710184B2 (en) | 1999-09-16 |
| US7198787B2 (en) | 2007-04-03 |
| BR9708049A (pt) | 1999-07-27 |
| CA2248620A1 (en) | 1997-09-18 |
| US20020151689A1 (en) | 2002-10-17 |
| PL328804A1 (en) | 1999-02-15 |
| IL126014A0 (en) | 1999-05-09 |
| HUP9901597A3 (en) | 2000-06-28 |
| EP0954329A1 (en) | 1999-11-10 |
| TR199801795T2 (xx) | 1998-12-21 |
| CN1218411A (zh) | 1999-06-02 |
| RU2182493C2 (ru) | 2002-05-20 |
| DE69714775D1 (de) | 2002-09-19 |
| AU2522997A (en) | 1997-10-01 |
| ATE222122T1 (de) | 2002-08-15 |
| HUP9901597A2 (hu) | 1999-08-30 |
| DE69714775T2 (de) | 2003-04-24 |
| JP2000507230A (ja) | 2000-06-13 |
| NZ331763A (en) | 2000-01-28 |
| EP0954329B1 (en) | 2002-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Arditti et al. | Apoptotic killing of B-chronic lymphocytic leukemia tumor cells by allicin generated in situ using a rituximab-alliinase conjugate | |
| Jansen et al. | Immunotoxins in cancer therapy | |
| SK125798A3 (en) | Method of killing target cells in harvested cell populations with one or more immunotoxins | |
| MINCHEVA‐NILSSON et al. | Activated human γδ T lymphocytes express functional lactoferrin receptors | |
| JPH06501705A (ja) | 抗−腫瘍抗体及び生物学的活性剤の組合せによる相乗治療 | |
| Myklebust et al. | Comparison of two antibody-based methods for elimination of breast cancer cells from human bone marrow | |
| EP0507839B1 (en) | Method of separating haemopoietic progenitor cells | |
| EP0112093A3 (en) | Novel monoclonal hybridoma and corresponding antibody | |
| Shpall et al. | Transplantation of CD34+ hematopoietic progenitor cells | |
| Myklebust et al. | Eradication of small cell lung cancer cells from human bone marrow with immunotoxins | |
| CZ276398A3 (cs) | Immunotoxický prostředek pro ničení ; nežádoucích cílových buněk | |
| MXPA98007252A (en) | Method to destroy cells objective does not wish | |
| EP1794289B1 (en) | Method for ex-vivo purging in autologous transplantation using soluble fas-l molecules | |
| JP2006115826A (ja) | ナチュラルキラー細胞の増殖促進方法およびそれに用いる培養組成物 | |
| JP4106488B2 (ja) | 同種移植片に対する免疫寛容の誘導および／または白血病処置のための、幹細胞およびｃｄ６枯渇幹細胞の使用 | |
| EP1123384B1 (en) | Use of compositions depleted of dendritic cells for improving allogeneic hematopoietic cell transplantation | |
| Vogel et al. | Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells | |
| WO1989000583A1 (en) | Improved immunotoxin therapies utilizing purified ricin a-chain species | |
| KR19990087546A (ko) | 하나 이상의 면역독소로 수집된 세포군에 있는 표적 세포를 괴사시키는 방법 | |
| Claesson et al. | Effects of monoclonal anti‐T cell antibodies on rat cardiac allografts | |
| AU646011C (en) | Method of separating haemopoietic progenitor cells | |
| US20150098924A1 (en) | Method for ex-vivo purging in autologous transplantation | |
| Kvalheim et al. | Stem cell isolation with immunomagnetic beads and tumor cell contamination | |
| De Leij et al. | Bispecific monoclonal antibody (Biab)-retargeted cellular therapy for local treatment of cancer patients | |
| AU2122788A (en) | Improved immunotoxin therapies utilizing purified ricin a-chain species |